Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call Oct 24, 2024 04:00PM
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call Jul 25, 2024 04:00PM
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference May 30, 2024 04:01PM
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference May 6, 2024 04:01PM
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call Apr 25, 2024 04:01PM
View Older Stories

Feb 1, 2024 04:01PM Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
Oct 26, 2023 04:01PM Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
Oct 23, 2023 07:31AM Ironwood Pharma (IRWD) Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
Oct 23, 2023 07:30AM Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
Oct 16, 2023 06:00AM Ironwood Pharma (IRWD) Presents Positive Final Data from STARS Nutrition
Oct 16, 2023 06:00AM Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at Un
Oct 5, 2023 07:30AM Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Aug 8, 2023 07:00AM Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Jul 25, 2023 04:01PM Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
Jun 29, 2023 08:30AM Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
Jun 16, 2023 07:01AM Ironwood Pharma (IRWD) and VectivBio (VECT) Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
Jun 16, 2023 07:00AM Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
Jun 12, 2023 04:07PM Ironwood Pharma (IRWD) Announces FDA Approval of New Indication for LINZESS for Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
Jun 12, 2023 04:05PM Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
May 22, 2023 06:57AM Ironwood Pharma (IRWD) to Acquire VectivBio (VECT) for $17/sh Cash
May 22, 2023 06:57AM Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
May 9, 2023 04:01PM Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 8, 2023 07:30AM Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
May 4, 2023 07:00AM Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
Apr 24, 2023 07:30AM Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Apr 20, 2023 04:01PM Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
Feb 27, 2023 04:01PM Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
Feb 16, 2023 07:00AM Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
Feb 13, 2023 07:30AM Ironwood Pharma (IRWD) Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS
Feb 13, 2023 07:30AM Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ag
Feb 2, 2023 04:01PM Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
Jan 9, 2023 06:03AM Ironwood Pharma (IRWD) Updates FY22 Guidance, Issues FY2023 Outlook
Jan 9, 2023 06:00AM Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
Jan 4, 2023 04:01PM Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Nov 22, 2022 04:01PM Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 3, 2022 07:01AM Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Oct 20, 2022 04:01PM Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
Sep 6, 2022 07:01AM Ironwood Pharma (IRWD) Announces Positive Phase III Trial of LINZESS in Patients 6-17 with FC
Sep 6, 2022 07:00AM Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
Sep 1, 2022 04:01PM Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
Aug 4, 2022 07:00AM Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
Jul 21, 2022 04:01PM Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
May 25, 2022 07:30AM Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
May 9, 2022 08:00AM Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
May 5, 2022 07:00AM Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Apr 21, 2022 04:01PM Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
Mar 2, 2022 07:30AM Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 17, 2022 07:00AM Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
Feb 3, 2022 07:30AM Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
Jan 10, 2022 07:23AM Ironwood Pharma (IRWD) Provides Update on FY21 Guidance and Announces FY22 Guidance
Jan 10, 2022 07:20AM Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
Jan 5, 2022 07:30AM Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 1, 2021 07:34AM Ironwood Pharma (IRWD) Appoints Sravan K. Emany as Chief Financial Officer
Dec 1, 2021 07:30AM Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
Nov 4, 2021 07:15AM Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
View Older Stories